title: [Pharmacological treatment of obsessive compulsive disorder in children/adolescents].
abstract: Obsessive compulsive disorder (OCD) is a frequent condition. First-choice psychopharmacological treatment includes SSRIs where the choice of drug depends on the occurrence of side effects. If remission is obtained, continued treatment is recommended for at minimum of one year. If only a partial or no response is obtained, augmentation treatment with atypical antipsychotics may be attempted. However, only few studies have examined the effect and side effects of augmentation treatment in children and adolescents. The aim was to provide a summary on the current knowledge on psychopharmacological treatment of children and adolescents with OCD.
authors.affiliation: Århus Universitetshospital, Børne- og Ungdomspsykiatrisk Regionscenter, 8240 Risskov, Denmark. jbbn@dadlnet.dk
authors.forename: Judith Becker
authors.initials: JB
authors.lastname: Nissen
authors.forename: Per Hove
authors.initials: PH
authors.lastname: Thomsen
mesh_terms: D000293:Adolescent; D000928:Antidepressive Agents / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002648:Child; D015928:Cognitive Behavioral Therapy; D003193:Compulsive Personality Disorder / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D017410:Practice Guidelines as Topic; D011619:Psychotropic Drugs / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D011619:Psychotropic Drugs; D017367:Selective Serotonin Reuptake Inhibitors